Back to Search
Start Over
Ischemic Optic Neuropathy: A Review of Current and Potential Future Pharmacotherapies.
- Source :
-
Pharmaceuticals (14248247) . Oct2024, Vol. 17 Issue 10, p1281. 26p. - Publication Year :
- 2024
-
Abstract
- The treatment of arteritic anterior ischemic optic neuropathy (AAION), non-arteritic ischemic optic neuropathy (NAAION), and posterior ischemic optic neuropathy (PION) is a topic of ongoing research with mixed evidence on some pharmacotherapies and a need for more consensus. This manuscript provides an overview of these conditions' current, potential future, and attempted pharmacotherapies. AAION's current treatment regimen consists of high-dose steroids, with methotrexate, tocilizumab, and abatacept, being the most viable steroid-sparing therapy candidates. As for NAAION, the treatments being tried are vast, with mixed evidence supporting each modality. Similarly, despite the various treatment options explored, there still needs to be a universally effective therapy for PION. More research is needed to formulate an agreed-upon treatment regimen for these conditions. [ABSTRACT FROM AUTHOR]
- Subjects :
- *METHOTREXATE
*NEUROPATHY
*PIONS
*TOCILIZUMAB
*ABATACEPT
Subjects
Details
- Language :
- English
- ISSN :
- 14248247
- Volume :
- 17
- Issue :
- 10
- Database :
- Academic Search Index
- Journal :
- Pharmaceuticals (14248247)
- Publication Type :
- Academic Journal
- Accession number :
- 180486820
- Full Text :
- https://doi.org/10.3390/ph17101281